PDS Biotechnology Corp (PDSB)

Pharmaceutical Preparations · market cap $47M · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-12 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

PDS Biotechnology Corp (PDSB) is a micro-cap pharmaceutical company with a market cap of ~$42M, 24 employees, and ~$21.7M in cash (~14.9 months of runway). Its sole disclosed pipeline asset is a Phase 3 trial of pembrolizumab monotherapy in recurrent head and neck cancer, with the next public event being an August 12, 2026 earnings release.

The catalyst path

2026-11-12 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Pembrolizumab Monotherapy	Phase 3	Recurrent Head and Neck Cancer

Price & technical context

3-month

-16.5%

6-month

+16.4%

12-month

-29.7%

52-wk range

$0.20–$1.43

vs 50-day MA

+40.0%

vs 200-day MA

-10.8%

Realized vol

163.7%

Max drawdown

-95.1%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for PDSB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.